Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of “Moderate Buy” from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Free Report) has earned an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $74.38.

A number of brokerages have commented on APLS. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, May 8th. Mizuho decreased their target price on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, April 29th. Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 23rd. JPMorgan Chase & Co. lifted their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Finally, Piper Sandler assumed coverage on Apellis Pharmaceuticals in a research note on Friday. They set a “neutral” rating and a $46.00 price target for the company.

Read Our Latest Report on APLS

Insider Buying and Selling

In other news, insider Mark Jeffrey Delong sold 9,913 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $56.90, for a total value of $564,049.70. Following the completion of the transaction, the insider now owns 54,693 shares in the company, valued at $3,112,031.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the transaction, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Jeffrey Delong sold 9,913 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $56.90, for a total transaction of $564,049.70. Following the sale, the insider now directly owns 54,693 shares of the company’s stock, valued at approximately $3,112,031.70. The disclosure for this sale can be found here. Insiders have sold 192,012 shares of company stock valued at $9,608,319 in the last 90 days. 6.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals during the first quarter valued at about $29,000. Covestor Ltd grew its holdings in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Apellis Pharmaceuticals in the first quarter worth $89,000. CWA Asset Management Group LLC purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth $205,000. Finally, Woodward Diversified Capital LLC purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth $210,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS opened at $40.11 on Tuesday. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $4.87 billion, a price-to-earnings ratio of -11.59 and a beta of 0.95. The stock’s fifty day simple moving average is $47.94 and its 200 day simple moving average is $56.71. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The business had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The firm’s quarterly revenue was up 284.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.56) EPS. As a group, sell-side analysts forecast that Apellis Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

(Get Free Report

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

See Also

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.